Capacity Worries Fade for Biomanufacturing

Pharmaceutical Technology, Pharmaceutical Technology-07-02-2003, Volume 27, Issue 7

The DSM investment puts biomanufacturing capacity in the spotlight. Contract biomanufacturers are adding new capacity and sponsors are marketing their excess capacity.

Related Content:

OutsourcingOutsourcing OutlookPharmaceutical Technology-07-02-2003
How Integrated Project Delivery Enables Speed: A Phase-By-Phase Guide
Robust Bioanalytical Studies Can Aid in Regulatory Submissions
Drug Digest: Sterilization’s Horizon: Improving Automation, Single-Use Technologies, and Annex 1